Gamida Cell Revenue and Competitors
Estimated Revenue & Valuation
- Gamida Cell's estimated annual revenue is currently $19.7M per year.
- Gamida Cell's estimated revenue per employee is $155,000
- Gamida Cell's total funding is $267.8M.
Employee Data
- Gamida Cell has 127 Employees.
- Gamida Cell grew their employee count by -1% last year.
Gamida Cell Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.8M | 89 | 22% | N/A | N/A |
#2 | $156.1M | 505 | -5% | $145M | N/A |
#3 | $4.8M | 62 | -35% | $150M | N/A |
#4 | $30.4M | 157 | 25% | $180.7M | N/A |
#5 | $5.7M | 37 | -3% | N/A | N/A |
#6 | $256.3M | 697 | 26% | $168.5M | N/A |
#7 | $10.4M | 67 | 40% | N/A | N/A |
#8 | $13.2M | 85 | -4% | N/A | N/A |
#9 | $29.5M | 190 | 19% | N/A | N/A |
#10 | $3.4M | 22 | -58% | N/A | N/A |
What Is Gamida Cell?
Gamida Cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. We are building a broad pipeline based on our proprietary NAM technology platform. Our lead program, NiCord, is in phase 3 development for allogeneic bone marrow transplantation and was granted Breakthrough Therapy Designation by the FDA.
keywords:N/A
$267.8M
Total Funding
127
Number of Employees
$19.7M
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Gamida Cell News
GDA-201 is an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas, Gamida...
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy...
Paul Schloesser. Associate Editor. The small Boston-based cell therapy outfit Gamida Cell recently axed 10% of its workforce in order to...
Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day ● Company recently filed an IND application for GDA-201; FDA placed the application on Clinical Hold pending modifications to donor eligibility procedures and ster ...
Every investor in Gamida Cell Ltd. (NASDAQ:GMDA) should be aware of the most powerful shareholder groups. Insiders often own a large ...
Other Companies in Jerusalem
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $40.7M | 162 | 18% | N/A |
#2 | $7.5M | 177 | 5% | $140.2M |
#3 | $102M | 333 | 10% | N/A |
#4 | N/A | 340 | 39% | N/A |
#5 | $15M | 351 | 14% | $197.5M |
